On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success ...

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Squamous Cell Carcinoma.

US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications: Princeton, New Jersey Monday, December 30, 2024, ...

The FDA approved a subcutaneous injection version of Bristol Myers Squibb nivolumab and hyaluronidase-nvhy for the treatment of several cancers including melanoma, non-small cell lung cancer and renal ...

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic ...

CARsgen Therapeutics announces positive results from China GC/GEJ pivotal phase II trial of Claudin18.2 CAR-T: Shanghai, China Tuesday, December 31, 2024, 14:00 Hrs [IST] CARsgen ...

BMSs Opdivo gains FDA approval for faster subcutaneous cancer treatment BMS secures FDA nod for rapid cancer treatment ...

More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

The Food and Drug Administration announced it has approved nivolumab and hyaluronidase-nvhy, Opdivo Qvantig, from Bristol Myers (BMY) Squibb, ...

Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and ...